DOCSLIB.ORG

Overexpression of Hrad17 Mrna in Human Breast Cancer: Correlation with Lymph Node Metastasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overexpression of Hrad17 Mrna in Human Breast Cancer: Correlation with Lymph Node Metastasis Vol. 7, 2815–2820, September 2001 Clinical Cancer Research 2815 Overexpression of HRad17 mRNA in Human Breast Cancer: Correlation with Lymph Node Metastasis Akemi Kataoka, Noriaki Sadanaga, tasis in human breast cancers. Although its function still Koshi Mimori, Hiroaki Ueo, Graham F. Barnard, remains unclear, the expression of HRad17 mRNA could Keizo Sugimachi, Daniel Auclair, Lan Bo Chen,1 open up a new window for the diagnostic staging and treat- ment of human breast cancers. and Masaki Mori1 Department of Surgery, Medical Institute of Bioregulation, Kyushu INTRODUCTION University, Beppu 874-0838, Japan [A. K., N. S., M. M.]; Kimmel Cancer Institute, Jefferson Medical College, Philadelphia, In Schizosaccharomyces pombe, the products of six genes, Pennsylvania 19107 [K. M.]; Department of Surgery, Oita Prefectural Rad1, Rad3, Rad9, Rad17, Rad26, and Hus1, have been iden- Hospital, Oita 870-8511, Japan [H. U.]; Division of Digestive Disease tified as essential components of checkpoint pathways. Several and Nutrition, University of Massachusetts Medical Center, of these genes have structural homologues in the budding yeasts, Worcester, Massachusetts 01655 [G. F. B.]; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 and additional conservation across eukaryotes has been demon- [D. A., L. B. C.]; and Department of Surgery II, Faculty of Medicine, strated, e.g., human homologues of S. pombe Rad3, ataxia Kyushu University, Fukuoka 812-8582, Japan [K. S.] telangiectasia mutated (1), and ataxia telangiectasia- and Rad3- related; 2, 3); a human homologue of S. pombe Rad9, HRad9 (4); and a human homologue of S. pombe Rad1, HRad1 (5). ABSTRACT Recently, a human homologue of the S. pombe Rad17 check- Purpose: A novel human gene, designated HRad17, was point gene named HRad17 was identified (6–8). S. pombe identified as the human homologue of the Rad17 of Schizos- Rad17 is known to play critical roles in maintaining genomic accharomyces pombe and Rad24 of Saccharomyces cerevi- stability and integrity, as a G2-M checkpoint protein in the cell siae. In yeast, these genes play a critical role in maintaining cycle, and to prevent the development of cancer and hereditary genomic stability. The aim of this study was to evaluate the diseases; however, the function of HRad17 is still unclear. expression of HRad17 in human breast cancer. It was reported independently that HRad17 could be local- Experimental Design: We investigated HRad17 mRNA ized on human chromosome 4q or 5q by fluorescence in situ expression in 64 cases of human breast cancer by means of hybridization analysis (6, 7, 9). These regions are implicated in reverse-transcription-PCR, in situ hybridization, and immu- the etiology of a variety of human cancers, including breast nohistochemistry. cancer, hepatocellular carcinoma, small cell lung cancer, non- Results: The HRad17 mRNA was overexpressed in 35 small cell lung cancer, duodenal adenocarcinoma, and head and cases (54.7%). Twenty-four (68.6%) of 35 cases with neck squamous cell carcinoma (1, 10–13). IHC2 and RT-PCR HRad17 overexpression in cancer tissues were node-posi- analysis indicates elevated levels of expression of HRad17 in tive, whereas only 8 (27.6%) of 29 cases without HRad17 human testis and colon cancer (6). But there are no previous overexpressions were node-positive. The expression of reports studying the clinical significance of HRad17 expression HRad17 mRNA correlated with both lymph node metastasis in human cancer. Thus, we investigated its expression in human ؍ ؍ (P 0.001) and high Ki67 labeling index (P 0.006). breast cancer cell lines and in clinical breast cancers by means Although not significantly different, expression of HRad17 of RT-PCR and IHC using a monoclonal antibody to evaluate its ؍ mRNA tended to correlate with tumor size (P 0.06) and clinical significance. We also determined whether expression of ؍ expression of mutant p53 protein (P 0.10). Furthermore, HRad17 mRNA correlates with p53 mutation, overexpression of expression of HRad17 mRNA was an independent predictor oncoprotein c-erbB-2 (also known as HER2/neu), or Ki67 la- of axillary lymph node metastasis as well as of lymphatic beling index as a marker of proliferation. permeation by multivariate analysis (P < 0.0001). Conclusions: Our study demonstrates that HRad17 MATERIALS AND METHODS might be related to the development of lymph node metas- Tissue Specimens and Cell Lines. Sixty-four matched normal breast and breast cancer tissue samples were obtained from radical mastectomy performed at the Oita Prefectural Hos- pital (Beppu, Japan), the National Beppu Hospital (Beppu, Ja- Received 7/5/00; revised 5/22/01; accepted 5/31/01. pan), the Matsuyama Red Cross Hospital (Beppu, Japan), and The costs of publication of this article were defrayed in part by the the Medical Institute of Bioregulation, Kyushu University payment of page charges. This article must therefore be hereby marked (Beppu, Japan), between June 1998 and May 1999. Patients advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom requests for reprints should be addressed, at Dr. Lan Bo Chen, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115; Phone: (617) 632-3385; Fax: (617) 632-4470; or at Dr. Masaki 2 The abbreviations used are: IHC, immunohistochemistry; RT-PCR, Mori, Department of Surgery, Medical Institute of Bioregulation, reverse-transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehy- Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan. drogenase. Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2001 American Association for Cancer Research. 2816 HRad17 Expression in Breast Cancers were excluded if they had received preoperative neoadjuvant Table 1 Clinico-pathological data of 64 patients chemotherapy or radiotherapy. Specimens were frozen in liquid HRad17 mRNA nitrogen immediately after surgical resection and kept at Ϫ90°C until the extraction of RNA. Human breast cancer cell lines Negative Positive Factors (%) (%) P MCF-7, MRK-nu-1, YMB-1-E, and YMB-1 were used. RNA Extraction and RT-PCR. Total RNA was ex- Mean age (yr) 29 (45.3%) 35 (54.7%) Menopause 54.6 Ϯ 12.6 56.1 Ϯ 12.0 NSa tracted by the acid guanidium thiocyanate-phenol-chloroform Premenopausal 11 (34.5%) 11 (32.8%) NS extraction procedure. The cDNA was synthesized from 2.5 ␮g Postmenopausal 19 (65.5%) 24 (67.2%) of total RNA as described previously (14). HRad17-specific Tumor size (cm) PCR was performed with primers 5Ј-TCCTTAGAACAGATT- Յ2.0 14 (48.3%) 9 (25.7%) 0.06 Ј Ј Ն2.1 15 (51.7%) 26 (74.3%) TATGGTTTA-3 and 5 -ATACTTTACATGAAGTTCTA- Ϯ Ϯ Ј Mean 2.4 1.4 2.8 1.6 AGGA-3 to amplify a 523-bp fragment. To prevent amplifica- Histological subtype tion from eventual contamination genomic DNA, these primers NIDC 1 (3.5%) 0 (0%) NS are located in different exons. PCR was performed for 26 cycles IDC 27 (93.0%) 30 (88.6%) (45sat94°C; 45 s at 60°C; and 45 s at 72°C). Five-␮l aliquots Other 1 (3.5%) 4 (11.4%) Lymph node metastasis of the PCR products were size-fractionated on a 1.5% agarose Negative 21 (72.4%) 11 (31.4%) 0.001 gel and visualized after ethidium bromide staining. The PCR Positive 8 (27.6%) 24 (68.6%) products were subcloned into the pCR II vector (Invitrogen) and Lymphatic permeation verified by sequencing (ABI100 version 3.3; ABI PRISM). Negative 17 (58.6%) 16 (45.7%) NS RNA quality was verified by running RT-PCR reactions for Positive 12 (41.4%) 19 (54.3%) Vascular invasion GAPDH on each RNA sample (14). Primer sequences for Negative 25 (86.2%) 29 (82.9%) NS GAPDH were 5GTCAACGGATTTGGTCTGTATT-3Ј and 5Ј- Positive 4 (13.8%) 6 (17.1%) AGTCTTCTGGGTGGCAGTGAT-3Ј(product size, 560 bp), ER status and PCR was performed for 22 cycles (60 s at 94°C; 60 s at Negative 8 (27.6%) 15 (42.9%) NS Positive 20 (69.0%) 19 (54.3%) 56°C; and 60 s at 72°C). Each series of RT-PCR reactions had Unknown 1 (3.5%) 1 (2.9%) a sample without RNA as a negative control, and all specimens PR status were analyzed at least twice. Negative 10 (34.5%) 17 (48.6%) NS In Situ RNA Hybridization. In situ RNA hybridization Positive 18 (62.1%) 17 (48.6%) was performed using a nonradioactive RNA color kit Unknown 1 (3.5%) 1 (2.9%) p53 proteinb (RPN3300; Amersham Pharmacia). A 523-bp PCR product was Negative 20 (69.0%) 17 (48.6%) 0.10 subcloned into TA vectors (pCR II; Invitrogen). The plasmid Positive 9 (31.0%) 18 (51.4%) DNA was isolated and purified using the RPM kit (BIO 101; Overexpression of c-erbB-2c Biotechnologies, Inc.), and fragments corresponding to the Negative 26 (89.7%) 27 (77.1%) NS Ј Positive 3 (10.3%) 8 (22.9%) COOH terminus and 3 region of Hrad17 were excised using Ki67 labeling index (%)d XhoI (Takara Co., Kyoto, Japan). Riboprobes were generated Ͻ8.3 20 (69.0%) 12 (34.2%) 0.006 with T7 and SP6 RNA polymerase. Ն8.3 9 (31.0%) 23 (65.8%) IHC. We used mouse monoclonal antibodies 31E9 for a NS, not significant; NIDC, non-invasive ductal carcinoma; IDC, HRad17 protein (6, 15), DO-7 (Dako Co.) for p53, and NCL- invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone Ki67-MM1 (NovoCastra Laboratories, Ltd.) for Ki67. Rabbit receptor. b Ͼ polyclonal antibody (Nichirei Co., Tokyo, Japan) was used for p53 protein was judged as positive when 10% of cancer cells ␮ were stained with DO-7 by IHC. the detection of overexpression of c-erbB-2. Five- m-thick c Overexpression of c-erbB-2, judged as positive when Ͼ10% of sections of formalin-fixed and paraffin-embedded tissue sam- cancer cells were stained membrane with polyclonal antibody.
Load more

Recommended publications
  • ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
    Published OnlineFirst March 24, 2014; DOI: 10.1158/0008-5472.CAN-13-3229 Cancer Therapeutics, Targets, and Chemical Biology Research ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency Kareem N. Mohni, Gina M. Kavanaugh, and David Cortez Abstract The DNA damage response kinase ATR and its effector kinase CHEK1 are required for cancer cells to survive oncogene-induced replication stress. ATR inhibitors exhibit synthetic lethal interactions, with deficiencies in the DNA damage response enzymes ATM and XRCC1 and with overexpression of the cell cycle kinase cyclin E. Here, we report a systematic screen to identify synthetic lethal interactions with ATR pathway–targeted drugs, rationalized by their predicted therapeutic utility in the oncology clinic. We found that reduced function in the ATR pathway itself provided the strongest synthetic lethal interaction. In addition, we found that loss of the structure-specific endonuclease ERCC1-XPF (ERCC4) is synthetic lethal with ATR pathway inhibitors. ERCC1- deficient cells exhibited elevated levels of DNA damage, which was increased further by ATR inhibition. When treated with ATR or CHEK1 inhibitors, ERCC1-deficient cells were arrested in S-phase and failed to complete cell-cycle transit even after drug removal. Notably, triple-negative breast cancer cells and non–small cell lung cancer cells depleted of ERCC1 exhibited increased sensitivity to ATR pathway–targeted drugs. Overall, we concluded that ATR pathway–targeted drugs may offer particular utility in cancers with reduced ATR pathway function or reduced levels of ERCC4 activity. Cancer Res; 74(10); 1–11. Ó2014 AACR. Introduction repair pathway such as homologous recombination or post- – Replicating DNA is sensitive to a wide array of endogenous replicative repair to remove the PARP DNA complexes (7).
    [Show full text]
  • Genome-Wide Parent-Of-Origin DNA Methylation Analysis Reveals The
    Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Research Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment Franck Court,1,15 Chiharu Tayama,2,15 Valeria Romanelli,1,15 Alex Martin-Trujillo,1,15 Isabel Iglesias-Platas,3 Kohji Okamura,4 Naoko Sugahara,2 Carlos Simo´n,5 Harry Moore,6 Julie V. Harness,7 Hans Keirstead,7 Jose Vicente Sanchez-Mut,8 Eisuke Kaneki,9 Pablo Lapunzina,10 Hidenobu Soejima,11 Norio Wake,9 Manel Esteller,8,12,13 Tsutomu Ogata,14 Kenichiro Hata,2 Kazuhiko Nakabayashi,2,16,17 and David Monk1,16,17 1–14[Author affiliations appear at the end of the paper.] Differential methylation between the two alleles of a gene has been observed in imprinted regions, where the methylation of one allele occurs on a parent-of-origin basis, the inactive X-chromosome in females, and at those loci whose methylation is driven by genetic variants. We have extensively characterized imprinted methylation in a substantial range of normal human tissues, reciprocal genome-wide uniparental disomies, and hydatidiform moles, using a combination of whole- genome bisulfite sequencing and high-density methylation microarrays. This approach allowed us to define methylation profiles at known imprinted domains at base-pair resolution, as well as to identify 21 novel loci harboring parent-of-origin methylation, 15 of which are restricted to the placenta. We observe that the extent of imprinted differentially methylated regions (DMRs) is extremely similar between tissues, with the exception of the placenta.
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]
  • Lineage-Specific Programming Target Genes Defines Potential for Th1 Temporal Induction Pattern of STAT4
    Downloaded from http://www.jimmunol.org/ by guest on October 1, 2021 is online at: average * The Journal of Immunology published online 26 August 2009 from submission to initial decision 4 weeks from acceptance to publication J Immunol http://www.jimmunol.org/content/early/2009/08/26/jimmuno l.0901411 Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming Seth R. Good, Vivian T. Thieu, Anubhav N. Mathur, Qing Yu, Gretta L. Stritesky, Norman Yeh, John T. O'Malley, Narayanan B. Perumal and Mark H. Kaplan Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2009/08/26/jimmunol.090141 1.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* • Why • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of October 1, 2021. Published August 26, 2009, doi:10.4049/jimmunol.0901411 The Journal of Immunology Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming1 Seth R. Good,2* Vivian T. Thieu,2† Anubhav N. Mathur,† Qing Yu,† Gretta L.
    [Show full text]
  • Analysis of Alternative Splicing Associated with Aging and Neurodegeneration in the Human Brain
    Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Research Analysis of alternative splicing associated with aging and neurodegeneration in the human brain James R. Tollervey,1 Zhen Wang,1 Tibor Hortoba´gyi,2 Joshua T. Witten,1 Kathi Zarnack,3 Melis Kayikci,1 Tyson A. Clark,4 Anthony C. Schweitzer,4 Gregor Rot,5 Tomazˇ Curk,5 Blazˇ Zupan,5 Boris Rogelj,2 Christopher E. Shaw,2 and Jernej Ule1,6 1MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, United Kingdom; 2MRC Centre for Neurodegeneration Research, King’s College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, United Kingdom; 3EMBL–European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom; 4Expression Research, Affymetrix, Inc., Santa Clara, California 95051, USA; 5Faculty of Computer and Information Science, University of Ljubljana, Trzˇasˇka 25, SI-1000 Ljubljana, Slovenia Age is the most important risk factor for neurodegeneration; however, the effects of aging and neurodegeneration on gene expression in the human brain have most often been studied separately. Here, we analyzed changes in transcript levels and alternative splicing in the temporal cortex of individuals of different ages who were cognitively normal, affected by frontotemporal lobar degeneration (FTLD), or affected by Alzheimer’s disease (AD). We identified age-related splicing changes in cognitively normal individuals and found that these were present also in 95% of individuals with FTLD or AD, independent of their age. These changes were consistent with increased polypyrimidine tract binding protein (PTB)– dependent splicing activity. We also identified disease-specific splicing changes that were present in individuals with FTLD or AD, but not in cognitively normal individuals.
    [Show full text]
  • Signature of Progression and Negative Outcome in Colorectal Cancer
    Oncogene (2010) 29, 876–887 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc ORIGINAL ARTICLE A ‘DNA replication’ signature of progression and negative outcome in colorectal cancer M-J Pillaire1,7, J Selves2,7, K Gordien2, P-A Gouraud3, C Gentil3, M Danjoux2,CDo3, V Negre4, A Bieth1, R Guimbaud2, D Trouche5, P Pasero6,MMe´chali6, J-S Hoffmann1 and C Cazaux1 1Genetic Instability and Cancer Group, Department Biology of Cancer, Institute of Pharmacology and Structural Biology, UMR5089 CNRS, University of Toulouse, University Paul Sabatier, Toulouse, France; 2INSERM U563, Federation of Digestive Cancerology and Department of Anatomo-pathology, University of Toulouse, University Paul Sabatier, Toulouse, France; 3Service of Epidemiology, INSERM U558, Faculty of Medicine, University of Toulouse, University Paul Sabatier, Alle´es Jules Guesde, Toulouse, France; 4aCGH GSO Canceropole Platform, INSERM U868, Val d’Aurelle, Montpellier, France; 5Laboratory of Cellular and Molecular Biology of Cell Proliferation Control, UMR 5099 CNRS, University of Toulouse, University Paul Sabatier, Toulouse, France and 6Institute of Human Genetics UPR1142 CNRS, Montpellier, France Colorectal cancer is one of the most frequent cancers Introduction worldwide. As the tumor-node-metastasis (TNM) staging classification does not allow to predict the survival of DNA replication in normal cells is regulated by an patients in many cases, additional prognostic factors are ‘origin licensing’ mechanism that ensures that it occurs needed to better forecast their outcome. Genes involved in just once per cycle. Once cells enter the S-phase, the DNA replication may represent an underexplored source stability of DNA replication forks must be preserved to of such prognostic markers.
    [Show full text]
  • Dual Function of C/D Box Small Nucleolar Rnas in Rrna PNAS PLUS Modification and Alternative Pre-Mrna Splicing
    Dual function of C/D box small nucleolar RNAs in rRNA PNAS PLUS modification and alternative pre-mRNA splicing Marina Falaleevaa, Amadis Pagesb, Zaneta Matuszeka, Sana Hidmic, Lily Agranat-Tamirc, Konstantin Korotkova, Yuval Nevod, Eduardo Eyrasb,e, Ruth Sperlingc, and Stefan Stamma,1 aDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40536; bDepartment of Experimental and Health Sciences, Universitat Pompeu Fabra, E08003 Barcelona, Spain; cDepartment of Genetics, Hebrew University of Jerusalem, 91904 Jerusalem, Israel; dDepartment of Microbiology and Molecular Genetics, Computation Center at the Hebrew University and Hadassah Medical Center, 91904 Jerusalem, Israel; and eCatalan Institution for Research and Advanced Studies, E08010 Barcelona, Spain Edited by James E. Dahlberg, University of Wisconsin Medical School, Madison, WI, and approved February 5, 2016 (received for review October 1, 2015) C/D box small nucleolar RNAs (SNORDs) are small noncoding RNAs, SNORD fragments are not microRNAs, which have an average and their best-understood function is to target the methyltrans- length of 21–22 nt (13–16), and suggests that these fragments may ferase fibrillarin to rRNA (for example, SNORD27 performs 2′-O- have additional functions. methylation of A27 in 18S rRNA). Unexpectedly, we found a subset The association of some SNORDs with specific diseases sug- of SNORDs, including SNORD27, in soluble nuclear extract made gests that they may possess functions in addition to directing the under native conditions, where fibrillarin was not detected, indi- 2′-O-methylation of rRNA. For example, the loss of SNORD116 cating that a fraction of the SNORD27 RNA likely forms a protein expression is a decisive factor in Prader–Willi syndrome, the most complex different from canonical snoRNAs found in the insoluble common genetic cause for hyperphagia and obesity (17, 18).
    [Show full text]
  • Mutational Screening of Splicing Factor Genes in Cases with Autosomal Dominant Retinitis Pigmentosa
    Mutational screening of splicing factor genes in cases with autosomal dominant retinitis pigmentosa The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Benaglio, Paola, Patricia Fernandez San Jose, Almudena Avila- Fernandez, Giulia Ascari, Shyana Harper, Gaël Manes, Carmen Ayuso, Christian Hamel, Eliot L. Berson, and Carlo Rivolta. 2014. “Mutational screening of splicing factor genes in cases with autosomal dominant retinitis pigmentosa.” Molecular Vision 20 (1): 843-851. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406726 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Molecular Vision 2014; 20:843-851 <http://www.molvis.org/molvis/v20/843> © 2014 Molecular Vision Received 27 January 2014 | Accepted 16 June 2014 | Published 18 June 2014 Mutational screening of splicing factor genes in cases with autosomal dominant retinitis pigmentosa Paola Benaglio,1 Patricia Fernandez San Jose,2,3 Almudena Avila-Fernandez,2,3 Giulia Ascari,1 Shyana Harper,4 Gaël Manes,5 Carmen Ayuso,2,3 Christian Hamel,5 Eliot L. Berson,4 Carlo Rivolta1 1Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland; 2Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain; 3Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain; 4The Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear, Boston, MA; 5INSERM U1051, Institut des Neurosciences de Montpellier, Hôpital Saint Eloi, Montpellier, France Purpose: Mutations in genes encoding proteins from the tri-snRNP complex of the spliceosome account for more than 12% of cases of autosomal dominant retinitis pigmentosa (adRP).
    [Show full text]
  • A Review of Prostate Cancer Genome-Wide Association Studies (GWAS)
    Published OnlineFirst January 18, 2018; DOI: 10.1158/1055-9965.EPI-16-1046 Review Cancer Epidemiology, Biomarkers A Review of Prostate Cancer Genome-Wide & Prevention Association Studies (GWAS) Sarah Benafif1, Zsofia Kote-Jarai1, and Rosalind A. Eeles1,2, on behalf of the PRACTICAL Consortium Abstract Prostate cancer is the most common cancer in men in for population-based risk stratification to target prostate Europe and the United States. The genetic heritability of cancer screening to men with an increased genetic risk of prostate cancer is contributed to by both rarely occurring disease development, while for those who develop prostate genetic variants with higher penetrance and moderate cancer, identifying genetic variants could allow treatment to commonly occurring variants conferring lower risks. to be tailored based on a genetic profile in the early disease The number of identified variants belonging to the latter setting. Functional studies of identified variants are needed category has increased dramatically in the last 10 years with to fully understand underlying mechanisms of disease the development of the genome-wide association study and identify novel targets for treatment. This review will (GWAS) and the collaboration of international consortia outline the GWAS carried out in prostate cancer and the that have led to the sharing of large-scale genotyping data. common variants identified so far, and how these may be Over 40 prostate cancer GWAS have been reported, with utilized clinically in the screening for and management of approximately 170 common variants now identified. prostate cancer. Cancer Epidemiol Biomarkers Prev; 27(8); 845–57. Clinical utility of these variants could include strategies Ó2018 AACR.
    [Show full text]
  • Compound Heterozygous Mutations in the Noncoding RNU4ATAC Cause Roifman Syndrome by Disrupting Minor Intron Splicing
    ARTICLE Received 2 Feb 2015 | Accepted 25 Sep 2015 | Published 2 Nov 2015 DOI: 10.1038/ncomms9718 OPEN Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing Daniele Merico1,*, Maian Roifman2,3,4,*, Ulrich Braunschweig5,RyanK.C.Yuen1, Roumiana Alexandrova1, Andrea Bates6, Brenda Reid6, Thomas Nalpathamkalam1,ZhuozhiWang1, Bhooma Thiruvahindrapuram1, Paul Gray7, Alyson Kakakios8, Jane Peake9,10, Stephanie Hogarth9,10,DavidManson11, Raymond Buncic12, Sergio L. Pereira1, Jo-Anne Herbrick1,BenjaminJ.Blencowe5,13,ChaimM.Roifman4,6 &StephenW.Scherer1,13,14,15 Roifman Syndrome is a rare congenital disorder characterized by growth retardation, cognitive delay, spondyloepiphyseal dysplasia and antibody deficiency. Here we utilize whole-genome sequencing of Roifman Syndrome patients to reveal compound heterozygous rare variants that disrupt highly conserved positions of the RNU4ATAC small nuclear RNA gene, a minor spliceosome component that is essential for minor intron splicing. Targeted sequencing confirms allele segregation in six cases from four unrelated families. RNU4ATAC rare variants have been recently reported to cause microcephalic osteodysplastic primordial dwarfism, type I (MOPD1), whose phenotype is distinct from Roifman Syndrome. Strikingly, all six of the Roifman Syndrome cases have one variant that overlaps MOPD1-implicated structural elements, while the other variant overlaps a highly conserved structural element not previously implicated in disease. RNA-seq analysis confirms extensive and specific defects of minor intron splicing. Available allele frequency data suggest that recessive genetic disorders caused by RNU4ATAC rare variants may be more prevalent than previously reported. 1 The Centre for Applied Genomics (TCAG), Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada M5G 0A4.
    [Show full text]
  • DNA Distress: Just Ring 9-1-1 [9,11]
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Dispatch R733 DNA Distress: Just Ring 9-1-1 [9,11]. Interestingly, the Rad9 carboxyl terminus plays an important role in activation of the DNA damage The Rad9–Hus1–Rad1 checkpoint clamp (9-1-1) is a central player in the cellular checkpoint, which halts cell cycle response to DNA damage; three groups have determined the crystal structure progression to provide time for of 9-1-1, providing new insight into its loading mechanism and association with DNA repair [1]. Phosphorylation of DNA damage checkpoint and repair enzymes. this domain is required for binding and recruiting TopBP1 to sites of Michael Kemp and Aziz Sancar PCNA and 9-1-1 require the DNA damage [17] in order to activity of heteropentameric clamp activate the DNA damage response The genome is constantly exposed to loading complexes termed replication kinase ATR [18]. Unfortunately, to cellular metabolites and exogenous factor C (RFC) and Rad17-RFC, obtain recombinant 9-1-1 protein agents that induce lesions in DNA respectively, which bind to, open, suitable for crystallization, all capable of causing mutation, cancer, and clamp the complexes around three groups [9–11] used a truncated or cell death. In response to such DNA [13]. Whereas PCNA is loaded form of Rad9 lacking this region, damage, eukaryotic cells activate onto 30-primer–template junctions and hence the structures provide signaling pathways that promote DNA by the canonical RFC made up of no insight into the role of the Rad9 repair, allow bypass of lesions during RFC1–5, 9-1-1 is instead preferentially carboxyl terminus in the checkpoint DNA replication, and halt cell-cycle loaded onto 50-recessed ends by response.
    [Show full text]
  • Hunter Et Al CLSPN
    bioRxiv preprint doi: https://doi.org/10.1101/358291; this version posted June 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Regulation of checkpoint kinase signalling and tumorigenesis by the NF-κB regulated gene, CLSPN Jill E. Hunter1, Jacqueline A. Butterworth1, Helene Sellier1, Saimir Luli2, Achilleas Floudas2, Adam J. Moore1, Huw D. Thomas3, Kirsteen J. Campbell4, Niall S. Kenneth1, Robson T. Chiremba1, Dina Tiniakos2, Andrew M. Knight2, Benjamin E. Gewurz5, Fiona Oakley2, Michelle D. Garrett6,7, Ian Collins7, and Neil D. Perkins1* 1Institute for Cell and Molecular Biosciences 2Institute of Cellular Medicine 3Northern Institute for Cancer Research Faculty of Medical Sciences Newcastle University Newcastle Upon Tyne, NE2 4HH, UK 4The Beatson Institute for Cancer Research Glasgow, G61 1BD, UK 5Brigham and Women's Hospital, Boston, MA 02115, USA 6School of Biosciences, University of Kent Canterbury, CT2 7NJ, UK 7The Institute of Cancer Research Sutton, SM2 5NG, UK * corresponding author Tel. 0191 2088866 Fax. 0191 2087424 Email: [email protected] Running Title: NF-κB regulation of CHK1 inhibitor sensitivity Word count: 1 bioRxiv preprint doi: https://doi.org/10.1101/358291; this version posted June 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Inhibition of the tumour promoting activities of NF-κB by cell signalling pathways has been proposed as a natural mechanism to limit the development of cancer. However, there has been a lack of evidence for these effects in vivo.
    [Show full text]